总体来看，个股呈普涨态势，上涨个股近4900只。截至午间收盘，沪指报3880.22，涨1.13%；深成指报12841.60点，涨 2.04%；创指报3005.23点，涨2.60%。盘面上，F5G概念、CPO、光纤概念涨幅居前，中船系、机场航运、养殖业板块跌幅居 前。 三大指数早盘高开高走，深成指、创指双双涨超2%，沪指涨超1%。 板块方面，算力硬件股冲高走强，特发信息3连板；AI应用概念再度爆发，实达集团4连板，欢瑞世纪3连板；贵金属板块 拉升，西部黄金涨幅居前；抗流感概念持续走高，金迪克、海南海药、广济药业、特一药业涨停；下跌方面，中船系回调，中 船汉光领跌；水产概念调整，中水渔业跌停。 ...

盘面上，F5G概念、CPO、光纤概念涨幅居前，中船系、机场航运、养殖业板块跌幅居前。 热点板块： 1． AI应用概念 实达集团4连板，新华都、欢瑞世纪3连板，海天瑞声、石基信息、荣信文化、掌阅科技等跟涨。 消息面上，阿里旗下的AI助手千问App公测一周，下载量已突破1000万次，超越ChatGPT、Sora、 DeepSeek成为史上增长最快的AI应用。 11月25日消息，三大指数早盘高开高走，深成指、创指双双涨超2%，沪指涨超1%。板块方面，算力硬 件股冲高走强，特发信息（维权）3连板；AI应用概念再度爆发，实达集团（维权）4连板，欢瑞世纪3 连板；贵金属板块拉升，西部黄金涨幅居前；抗流感概念持续走高，金迪克、海南海药（维权）、广济 药业（维权）、特一药业涨停；下跌方面，中船系回调，中船汉光领跌；水产概念调整，中水渔业跌 停。总体来看，个股呈普涨态势，上涨个股近4900只。 2．光通信概念 光库科技20cm涨停，腾景科技涨超15%，双双创历史新高。 消息面上，近日，谷歌AI基础设施负责人Amin Vahdat日前在全体大会中表示，公司必须每6个月将AI算 力翻倍，并在未来4到5年内额外实现1000倍的增长， ...

| | | | | 沪深京重要指数 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 *● | 最新 | 涨幅% | | 涨跌 涨跌家数 张速% | | 总手 | 现手 金额 | | 上证指数 | 3880.22 | 1.13 | 43.45 | 2057/212 | -0.01 | 3.01亿 | 1.37万 4663.91亿 | | 深证成指 | 12841.60 | 2.04 | 256.52 | 2632/238 | 0.02 | 4.45 7. | 371 7077.33亿 | | 北证50 | 1408.85 | 1.65 | 22.81 | 258/23 | 0.02 | 392万 | 436 90.66 Z | | 创业板指 | 3005.23 | 2.60 | 76.19 | 1293/89 | 0.04 | 1.52 7. | 371 3478.68 7. | 盘面上热点轮番活跃，全市场近4900只个股上涨。从板块来看，算力硬件概念延续强势，特发信息3连 板，长飞光纤、汇绿生态涨停。AI应用概念再度爆发，实达集团4 ...

11月25日，千金药业盘中上涨2.01%，截至11:24，报10.66元/股，成交3572.82万元，换手率0.81%，总 市值52.47亿元。 资金流向方面，主力资金净流入361.13万元，特大单买入0.00元，占比0.00%，卖出104.55万元，占比 2.93%；大单买入886.25万元，占比24.81%，卖出420.56万元，占比11.77%。 千金药业今年以来股价涨3.29%，近5个交易日跌1.20%，近20日涨0.28%，近60日跌5.75%。 分红方面，千金药业A股上市后累计派现23.75亿元。近三年，累计派现4.49亿元。 机构持仓方面，截止2025年9月30日，千金药业十大流通股东中，景顺长城中证红利低波动100ETF （515100）位居第五大流通股东，持股297.40万股，为新进股东。天弘中证红利低波动100ETF （159549）位居第七大流通股东，持股241.73万股，为新进股东。招商成长量化选股股票A（020901） 位居第八大流通股东，持股237.18万股，为新进股东。汇添富中证中药ETF（560080）位居第十大流通 股东，持股212.67万股，为新进股东。招商量化精选股票发起 ...

11月25日，奥美医疗盘中上涨2.07%，截至10:43，报11.34元/股，成交4896.51万元，换手率0.96%，总 市值71.81亿元。 资金流向方面，主力资金净流入247.63万元，大单买入636.43万元，占比13.00%，卖出388.80万元，占 比7.94%。 奥美医疗今年以来股价涨30.78%，近5个交易日跌5.66%，近20日涨14.20%，近60日涨17.27%。 机构持仓方面，截止2025年9月30日，奥美医疗十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股1791.66万股，相比上期增加552.21万股。医疗器械ETF（159883）位居第十大流通股东， 持股156.56万股，为新进股东。 责任编辑：小浪快报 截至9月30日，奥美医疗股东户数3.78万，较上期增加0.71%；人均流通股11965股，较上期减少0.71%。 2025年1月-9月，奥美医疗实现营业收入25.97亿元，同比增长5.98%；归母净利润3.49亿元，同比增长 31.54%。 分红方面，奥美医疗A股上市后累计派现10.99亿元。近三年，累计派现9191.31万元。 资料显示，奥美医疗用品股份有限公司 ...

今年以来兄弟科技已经9次登上龙虎榜，最近一次登上龙虎榜为9月25日，当日龙虎榜净买入-5801.97万 元；买入总计1.27亿元 ，占总成交额比7.06%；卖出总计1.85亿元 ，占总成交额比10.28%。 11月25日，兄弟科技盘中上涨2.01%，截至10:06，报6.59元/股，成交3937.49万元，换手率0.86%，总市 值75.31亿元。 资金流向方面，主力资金净流入115.89万元，大单买入483.60万元，占比12.28%，卖出367.71万元，占 比9.34%。 兄弟科技今年以来股价涨55.06%，近5个交易日跌5.72%，近20日跌7.57%，近60日跌2.66%。 责任编辑：小浪快报 分红方面，兄弟科技A股上市后累计派现3.90亿元。近三年，累计派现1.06亿元。 机构持仓方面，截止2025年9月30日，兄弟科技十大流通股东中，国泰中证畜牧养殖ETF（159865）位 居第三大流通股东，持股1413.11万股，相比上期增加504.55万股。招商中证畜牧养殖ETF（516670）位 居第九大流通股东，持股204.98万股，为新进股东。 资料显示，兄弟科技股份有限公司位于浙江省海宁市海洲街道学 ...

贵州百灵今年以来股价涨47.27%，近5个交易日跌8.25%，近20日跌2.74%，近60日跌9.86%。 分红方面，贵州百灵A股上市后累计派现14.47亿元。近三年，累计派现0.00元。 11月21日，贵州百灵（维权）盘中下跌2.07%，截至10:09，报5.67元/股，成交4205.22万元，换手率 0.61%，总市值79.24亿元。 资金流向方面，主力资金净流出500.95万元，特大单买入0.00元，占比0.00%，卖出367.11万元，占比 8.73%；大单买入746.30万元，占比17.75%，卖出880.14万元，占比20.93%。 资料显示，贵州百灵企业集团制药股份有限公司位于贵州省安顺市经济技术开发区西航路212号，成立 日期1999年3月25日，上市日期2010年6月3日，公司主营业务涉及以苗药为主的中成药的生产、销售。 主营业务收入构成为：中成药86.97%，西药8.44%，医疗服务2.27%，其他1.91%，中药材0.42%。 贵州百灵所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：抗流感、低价、民营医院、 中药、肝炎治疗等。 截至11月10日，贵州百灵股东户数8.58万，较 ...

Core Insights - Hualan Vaccine's stock price decreased by 2.02% on November 20, trading at 22.34 CNY per share with a market capitalization of 13.43 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.63%, but a recent decline of 5.62% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Hualan Vaccine reported a revenue of 806 million CNY, a year-on-year decrease of 15.81%, and a net profit attributable to shareholders of 132 million CNY, down 50.51% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.037 billion CNY, with 957 million CNY distributed over the past three years [3] Shareholder Structure - As of October 20, 2025, the number of shareholders for Hualan Vaccine stands at 17,000, with an average of 35,332 circulating shares per person [2] - The top ten circulating shareholders include notable entities such as the China Southern Asset Management Co., which has reduced its holdings by 43,990 shares [3]

Core Viewpoint - The stock of Te Yi Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 35.94%, indicating volatility in its market performance [1]. Company Performance - As of September 30, 2025, Te Yi Pharmaceutical reported a revenue of 6.92 billion yuan, representing a year-on-year growth of 51.86%, and a net profit attributable to shareholders of 652.17 million yuan, which is a significant increase of 985.18% compared to the previous year [2]. - The company has distributed a total of 1.059 billion yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]. Stock Market Activity - The stock price of Te Yi Pharmaceutical is currently at 12.10 yuan per share, with a trading volume of 2.60 billion yuan and a turnover rate of 5.62%, leading to a total market capitalization of 6.207 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" 11 times this year, with the most recent appearance on November 17, where it recorded a net buy of -733.44 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical increased to 58,100, a rise of 10.11%, while the average circulating shares per person decreased by 9.09% to 6,481 shares [2]. - Among the top ten circulating shareholders, notable positions include the "Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A" and "Xingquan Hu-Shen 300 Index Enhanced (LOF) A," which maintained their holdings [3].

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 18.936 billion yuan, despite an overall increase of 86.44% year-to-date [1] Financial Performance - For the period from January to September 2025, Zhongsheng Pharmaceutical reported a revenue of 1.889 billion yuan, a year-on-year decrease of 1.01%, while the net profit attributable to shareholders increased by 68.40% to 251 million yuan [2] - The company has cumulatively distributed 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] Stock Market Activity - The stock has seen significant trading activity, with a net outflow of 67.267 million yuan in major funds recently, and it has appeared on the trading leaderboard seven times this year [1] - The stock price has fluctuated, with a recent 5-day decline of 5.75% and a 20-day increase of 20.89% [1] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 18.90% to 72,900, while the average number of circulating shares per person increased by 23.31% to 10,445 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited and several funds from Xingquan, indicating a mix of new and increasing positions among major shareholders [3]